Neuroprotection and neurotoxicity in the developing brain: an update on the effects of dexmedetomidine and xenon
| Autor: | Ka Chun Suen, Robert D. Sanders, Mervyn Maze, Azeem Alam, Daqing Ma, Zac Hana |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Agonist
Xenon medicine.drug_class Models Neurological Toxicology Bioinformatics Neuroprotection law.invention 03 medical and health sciences Cellular and Molecular Neuroscience 0302 clinical medicine Developmental Neuroscience Randomized controlled trial Models 030202 anesthesiology law Adrenergic alpha-2 Receptor Agonists Neurotoxicity medicine Animals Humans Anesthesia Clinical efficacy Dexmedetomidine Anesthetics Pediatric business.industry Neurosciences Brain medicine.disease Clinical trial Neuroprotective Agents Inhalation Anesthetics Inhalation Neurological Anesthetic Neurotoxicity Syndromes Cognitive Sciences business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Alam, A; Suen, KC; Hana, Z; Sanders, RD; Maze, M; & Ma, D. (2017). Neuroprotection and neurotoxicity in the developing brain: an update on the effects of dexmedetomidine and xenon. NEUROTOXICOLOGY AND TERATOLOGY, 60, 102-116. doi: 10.1016/j.ntt.2017.01.001. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/25k14822 |
| ISSN: | 0892-0362 |
| DOI: | 10.1016/j.ntt.2017.01.001 |
| Popis: | Growing and consistent preclinical evidence, combined with early clinical epidemiological observations, suggest potentially neurotoxic effects of commonly used anesthetic agents in the developing brain. This has prompted the FDA to issue a safety warning for all sedatives and anesthetics approved for use in children under three years of age. Recent studies have identified dexmedetomidine, the potent α2-adrenoceptor agonist, and xenon, the noble gas, as effective anesthetic adjuvants that are both less neurotoxic to the developing brain, and also possess neuroprotective properties in neonatal and other settings of acute ongoing neurologic injury. Dexmedetomidine and xenon are effective anesthetic adjuvants that appear to be less neurotoxic than other existing agents and have the potential to be neuroprotective in the neonatal and pediatric settings. Although results from recent clinical trials and case reports have indicated the neuroprotective potential of xenon and dexmedetomidine, additional randomized clinical trials corroborating these studies are necessary. By reviewing both the existing preclinical and clinical evidence on the neuroprotective effects of dexmedetomidine and xenon, we hope to provide insight into the potential clinical efficacy of these agents in the management of pediatric surgical patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect